Clinical Spectrum, Treatments and Outcomes of VEXAS Syndrome: A Multicenter Belgian Cohort

For decades, doctors have understood that the body's immune system can sometimes turn against itself, causing inflammation that attacks healthy tissue. These conditions, known as autoinflammatory diseases, were long thought to be inherited from birth, passed down through families like eye color or height. However, a major shift occurred in 2020 with the discovery of a new condition called VEXAS syndrome. This illness is different because it is not inherited; instead, it arises from a random, acquired change in a single gene within the body's blood-making cells. This change happens later in life, which is why the disease almost exclusively affects older men. The condition creates a chaotic mix of symptoms, from painful skin rashes and swollen joints to life-threatening blood disorders, leaving patients in a state of constant inflammation that is difficult to control.

A team of researchers across Belgium recently set out to understand exactly how this disease presents in their country. They gathered medical records from twenty-one men diagnosed with VEXAS syndrome at four major university hospitals. By looking closely at their histories, the scientists aimed to map the full range of symptoms, see how well current treatments worked, and understand the risks these patients face. Their work provides a clear picture of the disease's impact on a national level, highlighting both the successes of modern medicine and the persistent dangers that remain.

The men in this study were all older, with symptoms typically beginning around the age of sixty-eight. Almost every patient suffered from general signs of illness, such as extreme tiredness, weight loss, and night sweats. The disease did not stay in one place; it attacked multiple systems of the body. The most common targets were the skin, where patients developed painful rashes or sores, and the blood, where the body failed to produce enough healthy red blood cells. Many also experienced swelling in their joints and cartilage, particularly in the ears and nose, and a disturbingly high number suffered from blood clots. In nearly all cases, a blood test showed high levels of a protein called C-reactive protein, a standard marker that indicates the body is fighting a fire, even if the source was not an infection.

When the doctors looked at the blood cells under a microscope, they found a telltale sign of the disease: tiny empty spaces, or vacuoles, inside the blood-making cells. This feature, which gives the syndrome its name, was present in the majority of bone marrow samples examined. The genetic cause was also clear; every patient carried a specific mutation in the UBA1 gene, a change that disrupts how cells break down waste. While most patients had the same genetic error, a few had slightly different variations, yet all suffered from the same relentless inflammation.

Treating this condition proved to be a difficult balancing act. The first step for almost every patient was to use corticosteroids, powerful anti-inflammatory drugs that calm the immune system. While these drugs worked to reduce symptoms, they often had to be given at high doses for long periods, leading to significant side effects. Because the disease was so stubborn, many patients needed stronger, second-line treatments. Some received drugs that block a specific inflammatory signal called interleukin-6, while others were treated with medications that stop the overactive blood cells from dividing. A small number of patients underwent a bone marrow transplant, the only known cure, which involves replacing the patient's entire blood system with that of a healthy donor.

The results showed that these targeted therapies could be effective. Half of the patients treated with the interleukin-6 blockers achieved a state where their symptoms disappeared completely. Similarly, those who received bone marrow transplants or certain other drugs also saw their disease go into remission. However, the path to recovery was not without peril. The very treatments needed to calm the immune system left patients vulnerable to infections. The researchers recorded twenty-six separate infection episodes among the group, ranging from bacterial pneumonia to fungal infections. These infections were severe; four patients died from them, and another died from a heart attack, underscoring the fragility of these patients. In total, six men from the group passed away during the study period.

The study concludes that while doctors in Belgium have successfully identified and treated this complex disease, the road ahead remains challenging. The availability of the most effective, targeted drugs is limited by funding and regulations, forcing doctors to rely on compassionate access programs to get them to patients. The research confirms that VEXAS is a highly variable illness that strikes older men with a wide array of symptoms, but it also highlights a critical gap in care: the high risk of infection. Until better strategies are found to protect patients from these infections while controlling the disease, the mortality rate will remain a serious concern. This national snapshot serves as a call to action, urging authorities to recognize the urgent need for reliable access to life-saving therapies for this newly understood group of patients.